Protection of Saphenous Vein Graft from Arterial Pressure

Abstract

Background: Reoperations for bypass surgery increase the need for new grafts. We investigated early changes in both the normal human saphenous vein and in ectatic varicose veins externally supported by PTFE (polytetrafluoroethylene) graft and exposed to arterial pressure in an in vitro non-pulsatile flow model. Material and Methods: A total of 24 saphenous vein pieces (11 of them normal, the other 13 with varicosities) with a length of 6 centimeters were divided into equal parts; half of these parts were wrapped in PTFE grafts. All vein parts were placed in a perfusion circuit. Tissue biopsies were obtained from the vein segments. Light and electron microscopy examinations were performed, and endothelial continuity, elastic laminate continuity, medial connective tissue uniformity, medial smooth muscle uniformity, and adventitial connective tissue uniformity parameters were identified. Results: All parameters in the PTFE protected vein groups were better. The fewest morphological changes among all four groups were detected in the vein walls from normal veins with PTFE protection. There was no significant difference in endothelial continuity and adventitial connective tissue uniformity between the normal vein group and the varicose vein group with PTFE protection. Conclusions: It is suggested that supporting vein grafts externally with PTFE sufficiently protects the vein walls against damage from exposure to arterial pressure. If varicose veins are used as arterial grafts, supporting them with PTFE may be useful because of the good protection of endothelial and medial connective tissues, resulting in similar parameters to those of normal vein walls.

Key words

saphenous vein - varicose vein - graft patency - intimal injury

References

• 1 Alexander J H, Hafley G, Harrington R A, Peterson E D, Ferguson Jr T B, Lorenz T J, Goyal A, Gibson M, Mack M J, Gennevois D, Califf R M, Kouchoukos N T. PREVENT IV Investigators . Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery PREVENT IV: a randomized controlled trial.  JAMA. 2005;  16 2446-2454
• 2 Jeremy J Y, Mehta D, Bryan A J, Lewis D, Angelini G D. Platelets and saphenous vein graft failure following coronary artery bypass surgery.  Platelets. 1997;  8 295-309
• 3 Campeau L, Enjalbert M, Lesperance J, Vaislic C, Grondin C M, Bourassa M G. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10–12 years after surgery.  Circulation. 1983;  68 (3 pt 2) II1-II7
• 4 Lytle B W, Loop F D, Taylor P C, Goormastic M, Stewart R W, Novoa R, McCarthy P, Cosgrove D M. The effect of coronary reoperation on the survival of patients with stenosis in saphenous vein bypass grafts to coronary arteries.  J Thorac Cardiovasc Surg. 1993;  105 (4) 605-612 discussion 612-614
• 5 Stooker W, Niessen H W, Baidoshvili A, Wildevuur W R, Van Hinsbergh V W, Fritz J, Wildevuur C R, Eijsman L. Perivenous support reduces early changes in human vein grafts: studies in whole blood perfused human vein segments.  J Thorac Cardiovasc Surg. 2001;  121 (2) 290-297
• 6 Griffith G L, Allen K B, Waller B F, Heimansohn D A, Robison R J, Schier J J, Shaar C J. Endoscopic and traditional saphenous vein harvest: a histologic comparison.  Ann Thorac Surg. 2000;  69 (2) 520-523
• 7 Campeau L, Hunninghake D B, Knatterud G L, White C W, Domanski M, Forman S A, Forrester J S, Geller N L, Gobel F L, Herd J A, Hoogwerf B J, Rosenberg Y. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and the patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.  Circulation. 1999;  29 3241-3247
• 8 Chesebro J H, Clements I P, Fuster V, Elveback L R, Smith H C, Bardsley W T, Frye R L, Holmes Jr D R, Vlietstra R E, Pluth J R, Wallace R B, Puga F J, Orszulak T A, Piehler J M, Schaff H V, Danielson G K. A platelet-inhibitor drug trial in coronary artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency.  N Engl J Med. 1982;  8 73-78
• 9 O'Donohoe M K, Schwartz L B, Radic Z S, Mikat E M, McCann R L, Hagen P O. Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts.  Ann Surg. 1991;  214 (6) 727-732
• 10 Hirko M K, McShannic J R, Schmidt S P, Sharp W V, Evancho M M, Sims R L, Siebert J D. Pharmacologic modulation of intimal hyperplasia in canine vein interposition grafts.  J Vasc Surg. 1993;  17 (5) 877-887
• 11 Barra J A, Volant A, Leroy J P, Braesco J, Airiau J, Boschat J, Blanc J J, Penther P. Constrictive perivenous mesh prothesis for preservation of vein integrity. Experimental results and application for coronary bypass grafting.  J Thorac Cardiovasc Surg. 1986;  92 (3 Pt 1) 330-336
• 12 Moritz A, Raderer F, Magometschnigg H, Trubel W, Ullrich R, Laufer G, Staudacher M. The use of mesh-tube-constricted dilated varicose veins as arterial bypass conduit.  Thorac Cardiovasc Surg. 1992;  40 (6) 356-360
• 13 Angelini G D, Izzat M B, Bryan A J, Newby A C. External stenting reduces early medial and neointimal thickening in a pig model of arteriovenous bypass grafting.  J Thorac Cardiovasc Surg. 1996;  112 (1) 79-84
• 14 Barker S G, Talbert A, Cottam S, Baskerville P A, Martin J F. Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig.  Arterioscler Thromb. 1993;  13 (1) 70-77
• 15 Deriu G P, Ballotta E, Bonavina L, Alvino S, Franceschi L, Grego F, Thiene G. Great saphenous vein protection in arterial reconstructive surgery.  Eur J Vasc Surg. 1989;  3 (3) 253-260
• 16 Moritz A, Grabenwoger F, Wolner E. Mesh tube-calibrated varicose veins for coronary artery bypass grafting.  Ann Thorac Surg. 1994;  57 (1) 240-242
• 17 Zurbrügg H R, Knollmann F, Musci M, Wied M, Bauer M, Chavez T, Krukenberg A, Hetzer R. The biocompound method in coronary artery bypass operations: surgical technique and 3-year patency.  Ann Thorac Surg. 2000;  70 (5) 1536-1540
• 18 Zurbrügg H R, Hetzer R. The use of biocompound grafts together with varicose veins. First clinical experience.  J Cardiovasc Surg (Torino). 1996;  37 (6 Suppl. 1) 143-146
• 19 Zwolak R M, Adams M C, Clowes A W. Kinetics of vein graft hyperplasia: association with tangential stress.  J Vasc Surg. 1987;  5 (1) 126-136
• 20 Nomura H, Natio M, Igucji A, Thompson W D, Smith E B. Fibrin gel induces the migration of smooth muscle cells from rabbit aortic explants.  Thromb Haemost. 1999;  82 (4) 1347-1352
• 21 Grohs J G, Kadletz M, Wodratzka M, Wolner E, Raberger G. Contractile function of human veins after long-term storage in different media.  J Cardiovasc Pharmacol. 1996;  28 (1) 89-93
• 22 Schaeffer U, Tanner B, Strohschneider T, Stadtmüller A, Hannekum A. Damage to arterial and venous endothelial cells in bypass grafts induced by several solutions used in bypass surgery.  Thorac Cardiovasc Surg. 1997;  45 (4) 168-171
• 23 Cartier R, Bouchard D, Latulippe J F, Buluran J. Effect of solutions of preservation on the vascular reactivity of human saphenous veins.  Ann Chir. 1995;  49 (8) 728-734